Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21)
Funds smaller, higher-risk work on how GLP-1 and related drugs change cancer risk. No clinical trial in this version.
This is the exploratory companion to NIH's larger notice on the same question: how incretin mimetics — GLP-1 agonists, GIP-1 agents and dual GLP-1/GIP-1 drugs — affect cancer risk.
The evidence so far points both ways, with these drugs apparently raising the risk of some obesity-related cancers and lowering the risk of others, and the mechanisms are unexplained.
NIH's second goal is stated along…
Exploratory preclinical and patient-based studies of the mechanisms by which incretin mimetics affect cancer risk, at the scale and risk level of NIH's developmental grant. No clinical trial.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see how they score you
Sign up free to see the timeline
Sign up free to see where teams trip up